Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2016

03.02.2016 | Review

Innate Immunity and Inflammation in NAFLD/NASH

verfasst von: Marco Arrese, Daniel Cabrera, Alexis M. Kalergis, Ariel E. Feldstein

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Inflammation and hepatocyte injury and death are the hallmarks of nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), which is a currently burgeoning public health problem. Innate immune activation is a key factor in triggering and amplifying hepatic inflammation in NAFLD/NASH. Thus, identification of the underlying mechanisms by which immune cells in the liver recognize cell damage signals or the presence of pathogens or pathogen-derived factors that activate them is relevant from a therapeutic perspective. In this review, we present new insights into the factors promoting the inflammatory response in NASH including sterile cell death processes resulting from lipotoxicity in hepatocytes as well as into the altered gut-liver axis function, which involves translocation of bacterial products into portal circulation as a result of gut leakiness. We further delineate the key immune cell types involved and how they recognize both damage-associated molecular patterns or pathogen-associated molecular patterns through binding of surface-expressed pattern recognition receptors, which initiate signaling cascades leading to injury amplification. The relevance of modulating these inflammatory signaling pathways as potential novel therapeutic strategies for the treatment of NASH is summarized.
Literatur
1.
Zurück zum Zitat Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. (Epub ahead of print). doi:10.1016/j.cld.2015.10.001. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. (Epub ahead of print). doi:10.​1016/​j.​cld.​2015.​10.​001.
2.
Zurück zum Zitat Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:221–235.CrossRefPubMed Satapathy SK, Sanyal AJ. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:221–235.CrossRefPubMed
3.
Zurück zum Zitat Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology. 2014;147:754–764.CrossRefPubMed Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology. 2014;147:754–764.CrossRefPubMed
4.
Zurück zum Zitat Burt AD, Lackner C, Tiniakos DG. Diagnosis and assessment of NAFLD: definitions and histopathological classification. Semin Liver Dis. 2015;35:207–220.CrossRefPubMed Burt AD, Lackner C, Tiniakos DG. Diagnosis and assessment of NAFLD: definitions and histopathological classification. Semin Liver Dis. 2015;35:207–220.CrossRefPubMed
6.
Zurück zum Zitat Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.CrossRefPubMed Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.CrossRefPubMed
7.
Zurück zum Zitat Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.CrossRefPubMed Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253.CrossRefPubMed
9.
Zurück zum Zitat Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis. 2010;30:391–401.CrossRefPubMed Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis. 2010;30:391–401.CrossRefPubMed
10.
Zurück zum Zitat de la Higuera-Tijera F, Servin-Caamano AI. Pathophysiological mechanisms involved in nonalcoholic steatohepatitis and novel potential therapeutic targets. World J Hepatol. 2015;7:1297–1301.CrossRef de la Higuera-Tijera F, Servin-Caamano AI. Pathophysiological mechanisms involved in nonalcoholic steatohepatitis and novel potential therapeutic targets. World J Hepatol. 2015;7:1297–1301.CrossRef
11.
Zurück zum Zitat Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15:8591–8638.CrossRefPubMedPubMedCentral Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014;15:8591–8638.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Hirsova P, Gores GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol. 2015;1:17–27.CrossRefPubMedPubMedCentral Hirsova P, Gores GJ. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol. 2015;1:17–27.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta. 2010;1801:299–310.CrossRefPubMed Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta. 2010;1801:299–310.CrossRefPubMed
14.
15.
Zurück zum Zitat Zambo V, Simon-Szabo L, Szelenyi P, Kereszturi E, Banhegyi G, Csala M. Lipotoxicity in the liver. World J Hepatol. 2013;5:550–557.PubMedPubMedCentral Zambo V, Simon-Szabo L, Szelenyi P, Kereszturi E, Banhegyi G, Csala M. Lipotoxicity in the liver. World J Hepatol. 2013;5:550–557.PubMedPubMedCentral
16.
Zurück zum Zitat Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in nonalcoholic fatty liver disease. Biochim Biophys Acta. 2015;1852:1765–1778.CrossRefPubMed Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in nonalcoholic fatty liver disease. Biochim Biophys Acta. 2015;1852:1765–1778.CrossRefPubMed
18.
Zurück zum Zitat Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437–443.CrossRefPubMed Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003;125:437–443.CrossRefPubMed
19.
Zurück zum Zitat Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765–783. (e764).CrossRefPubMedPubMedCentral Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765–783. (e764).CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Wree A, Eguchi A, McGeough MD, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59:898–910.CrossRefPubMedPubMedCentral Wree A, Eguchi A, McGeough MD, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014;59:898–910.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Afonso MB, Rodrigues PM, Carvalho T, et al. Necroptosis is a key pathogenic event in human and experimental murine models of nonalcoholic steatohepatitis. Clin Sci (Lond). 2015;129:721–739.CrossRef Afonso MB, Rodrigues PM, Carvalho T, et al. Necroptosis is a key pathogenic event in human and experimental murine models of nonalcoholic steatohepatitis. Clin Sci (Lond). 2015;129:721–739.CrossRef
22.
Zurück zum Zitat Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol. 2011;5:201–212.CrossRefPubMedPubMedCentral Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol. 2011;5:201–212.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Mehal WZ. The inflammasome in liver injury and nonalcoholic fatty liver disease. Dig Dis. 2014;32:507–515.CrossRefPubMed Mehal WZ. The inflammasome in liver injury and nonalcoholic fatty liver disease. Dig Dis. 2014;32:507–515.CrossRefPubMed
25.
Zurück zum Zitat Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387–400.CrossRefPubMed Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387–400.CrossRefPubMed
27.
Zurück zum Zitat Jindal A, Bruzzi S, Sutti S, et al. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH). Exp Mol Pathol. 2015;99:155–162.CrossRefPubMed Jindal A, Bruzzi S, Sutti S, et al. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH). Exp Mol Pathol. 2015;99:155–162.CrossRefPubMed
29.
Zurück zum Zitat Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143:1158–1172.CrossRefPubMed Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143:1158–1172.CrossRefPubMed
30.
Zurück zum Zitat Miura K, Yang L, van Rooijen N, Brenner DA, Ohnishi H, Seki E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology. 2013;57:577–589.CrossRefPubMedPubMedCentral Miura K, Yang L, van Rooijen N, Brenner DA, Ohnishi H, Seki E. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology. 2013;57:577–589.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Garcia-Martinez I, Shaker ME, Mehal WZ. Therapeutic opportunities in damage-associated molecular pattern-driven metabolic diseases. Antioxid Redox Signal. 2015;23:1305–1315.CrossRefPubMedPubMedCentral Garcia-Martinez I, Shaker ME, Mehal WZ. Therapeutic opportunities in damage-associated molecular pattern-driven metabolic diseases. Antioxid Redox Signal. 2015;23:1305–1315.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Uchida K. Natural antibodies as a sensor of electronegative damage-associated molecular patterns (DAMPs). Free Radical Biol Med. 2014;72:156–161.CrossRef Uchida K. Natural antibodies as a sensor of electronegative damage-associated molecular patterns (DAMPs). Free Radical Biol Med. 2014;72:156–161.CrossRef
33.
Zurück zum Zitat Huebener P, Pradere JP, Hernandez C, et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2015;125:539–550.CrossRefPubMedPubMedCentral Huebener P, Pradere JP, Hernandez C, et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest. 2015;125:539–550.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008;48:322–335.CrossRefPubMed Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008;48:322–335.CrossRefPubMed
35.
36.
Zurück zum Zitat Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem. 2013;59:155–201.CrossRefPubMed Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem. 2013;59:155–201.CrossRefPubMed
37.
Zurück zum Zitat Bieghs V, Trautwein C. Innate immune signaling and gut-liver interactions in nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2014;3:377–385.PubMedPubMedCentral Bieghs V, Trautwein C. Innate immune signaling and gut-liver interactions in nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2014;3:377–385.PubMedPubMedCentral
38.
Zurück zum Zitat Netea MG, van der Meer JW. Immunodeficiency and genetic defects of pattern-recognition receptors. N Eng J Med. 2011;364:60–70.CrossRef Netea MG, van der Meer JW. Immunodeficiency and genetic defects of pattern-recognition receptors. N Eng J Med. 2011;364:60–70.CrossRef
39.
Zurück zum Zitat Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–820.CrossRefPubMed Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–820.CrossRefPubMed
40.
Zurück zum Zitat Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139:323–334. (e327).CrossRefPubMedPubMedCentral Miura K, Kodama Y, Inokuchi S, et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology. 2010;139:323–334. (e327).CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Ehses JA, Meier DT, Wueest S, et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia. 2010;53:1795–1806.CrossRefPubMed Ehses JA, Meier DT, Wueest S, et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia. 2010;53:1795–1806.CrossRefPubMed
42.
Zurück zum Zitat Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;1247:387–400.CrossRef Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;1247:387–400.CrossRef
43.
Zurück zum Zitat Wree A, McGeough MD, Pena CA, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berl). 2014;92:1069–1082.CrossRef Wree A, McGeough MD, Pena CA, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berl). 2014;92:1069–1082.CrossRef
44.
45.
Zurück zum Zitat Duarte N, Coelho IC, Patarrao RS, Almeida JI, Penha-Goncalves C, Macedo MP. How inflammation impinges on NAFLD: a role for Kupffer cells. Biomed Res Int. 2015;2015:984578.CrossRefPubMedPubMedCentral Duarte N, Coelho IC, Patarrao RS, Almeida JI, Penha-Goncalves C, Macedo MP. How inflammation impinges on NAFLD: a role for Kupffer cells. Biomed Res Int. 2015;2015:984578.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Lanthier N. Targeting Kupffer cells in nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: why and how? World J Hepatol. 2015;7:2184–2188.CrossRefPubMedPubMedCentral Lanthier N. Targeting Kupffer cells in nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: why and how? World J Hepatol. 2015;7:2184–2188.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59:1393–1405.CrossRefPubMed Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology. 2014;59:1393–1405.CrossRefPubMed
48.
Zurück zum Zitat Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol. 2014;60:1090–1096.CrossRefPubMed Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. J Hepatol. 2014;60:1090–1096.CrossRefPubMed
49.
Zurück zum Zitat Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577–594. (e571).CrossRefPubMed Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology. 2014;147:577–594. (e571).CrossRefPubMed
50.
Zurück zum Zitat Leroux A, Ferrere G, Godie V, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol. 2012;57:141–149.CrossRefPubMed Leroux A, Ferrere G, Godie V, et al. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol. 2012;57:141–149.CrossRefPubMed
51.
Zurück zum Zitat Sawada K, Ohtake T, Hasebe T, et al. Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of nonalcoholic fatty liver disease in mice. Hepatol Res. 2014;44:920–934.CrossRefPubMed Sawada K, Ohtake T, Hasebe T, et al. Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of nonalcoholic fatty liver disease in mice. Hepatol Res. 2014;44:920–934.CrossRefPubMed
52.
Zurück zum Zitat Fallowfield JA, Mizuno M, Kendall TJ, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol. 2007;178:5288–5295.CrossRefPubMed Fallowfield JA, Mizuno M, Kendall TJ, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol. 2007;178:5288–5295.CrossRefPubMed
53.
54.
Zurück zum Zitat Tacke F, Yoneyama H. From NAFLD to NASH to fibrosis to HCC: role of dendritic cell populations in the liver. Hepatology. 2013;58:494–496.CrossRefPubMed Tacke F, Yoneyama H. From NAFLD to NASH to fibrosis to HCC: role of dendritic cell populations in the liver. Hepatology. 2013;58:494–496.CrossRefPubMed
55.
Zurück zum Zitat Lukacs-Kornek V, Schuppan D. Dendritic cells in liver injury and fibrosis: shortcomings and promises. J Hepatol. 2013;59:1124–1126.CrossRefPubMed Lukacs-Kornek V, Schuppan D. Dendritic cells in liver injury and fibrosis: shortcomings and promises. J Hepatol. 2013;59:1124–1126.CrossRefPubMed
56.
Zurück zum Zitat Henning JR, Graffeo CS, Rehman A, et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology. 2013;58:589–602.CrossRefPubMedPubMedCentral Henning JR, Graffeo CS, Rehman A, et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology. 2013;58:589–602.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Sutti S, Locatelli I, Bruzzi S, et al. CX3CR1-expressing inflammatory dendritic cells contribute to the progression of steatohepatitis. Clin Sci (Lond). 2015;129:797–808.CrossRef Sutti S, Locatelli I, Bruzzi S, et al. CX3CR1-expressing inflammatory dendritic cells contribute to the progression of steatohepatitis. Clin Sci (Lond). 2015;129:797–808.CrossRef
58.
60.
Zurück zum Zitat Rensen SS, Bieghs V, Xanthoulea S, et al. Neutrophil-derived myeloperoxidase aggravates nonalcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PLoS One. 2012;7:e52411.CrossRefPubMedPubMedCentral Rensen SS, Bieghs V, Xanthoulea S, et al. Neutrophil-derived myeloperoxidase aggravates nonalcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PLoS One. 2012;7:e52411.CrossRefPubMedPubMedCentral
61.
Zurück zum Zitat Ibusuki R, Uto H, Arima S, et al. Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet. Liver Int. 2013;33:1549–1556.PubMed Ibusuki R, Uto H, Arima S, et al. Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet. Liver Int. 2013;33:1549–1556.PubMed
62.
Zurück zum Zitat Talukdar S, da Oh Y, Bandyopadhyay G, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med. 2012;18:1407–1412.CrossRefPubMedPubMedCentral Talukdar S, da Oh Y, Bandyopadhyay G, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med. 2012;18:1407–1412.CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Geissmann F, Cameron TO, Sidobre S, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005;3:e113.CrossRefPubMedPubMedCentral Geissmann F, Cameron TO, Sidobre S, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005;3:e113.CrossRefPubMedPubMedCentral
66.
Zurück zum Zitat Martin-Murphy BV, You Q, Wang H, et al. Mice lacking natural killer T cells are more susceptible to metabolic alterations following high fat diet feeding. PLoS One. 2014;9:e80949.CrossRefPubMedPubMedCentral Martin-Murphy BV, You Q, Wang H, et al. Mice lacking natural killer T cells are more susceptible to metabolic alterations following high fat diet feeding. PLoS One. 2014;9:e80949.CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Elinav E, Pappo O, Sklair-Levy M, et al. Adoptive transfer of regulatory NKT lymphocytes ameliorates nonalcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8 trapping. J Pathol. 2006;209:121–128.CrossRefPubMed Elinav E, Pappo O, Sklair-Levy M, et al. Adoptive transfer of regulatory NKT lymphocytes ameliorates nonalcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8 trapping. J Pathol. 2006;209:121–128.CrossRefPubMed
68.
Zurück zum Zitat Kremer M, Thomas E, Milton RJ, et al. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology. 2010;51:130–141.CrossRefPubMedPubMedCentral Kremer M, Thomas E, Milton RJ, et al. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology. 2010;51:130–141.CrossRefPubMedPubMedCentral
69.
Zurück zum Zitat Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2009;21:673–680.CrossRefPubMed Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2009;21:673–680.CrossRefPubMed
70.
Zurück zum Zitat Syn WK, Oo YH, Pereira TA, et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology. 2010;51:1998–2007.CrossRefPubMedPubMedCentral Syn WK, Oo YH, Pereira TA, et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology. 2010;51:1998–2007.CrossRefPubMedPubMedCentral
72.
Zurück zum Zitat Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and nonalcoholic fatty liver disease. Clin Biochem. 2015;48:923–930.CrossRefPubMed Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and nonalcoholic fatty liver disease. Clin Biochem. 2015;48:923–930.CrossRefPubMed
73.
Zurück zum Zitat Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013;56:461–468.CrossRefPubMedPubMedCentral Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013;56:461–468.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Federico A, Dallio M, Godos J, Loguercio C, Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res (Epub ahead of print). doi:10.1016/j.trsl.2015.08.002. Federico A, Dallio M, Godos J, Loguercio C, Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res (Epub ahead of print). doi:10.​1016/​j.​trsl.​2015.​08.​002.
75.
Zurück zum Zitat Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap–bile acids in metabolic control. Nat Rev Endocrinol. 2014;10:488–498.CrossRefPubMed Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap–bile acids in metabolic control. Nat Rev Endocrinol. 2014;10:488–498.CrossRefPubMed
76.
Zurück zum Zitat Liu HX, Keane R, Sheng L, Wan YY. Implications of microbiota and bile acid in liver injury and regeneration. J Hepatol. 2015;63:1502–1510.CrossRefPubMed Liu HX, Keane R, Sheng L, Wan YY. Implications of microbiota and bile acid in liver injury and regeneration. J Hepatol. 2015;63:1502–1510.CrossRefPubMed
77.
78.
Zurück zum Zitat Giorgio V, Miele L, Principessa L, et al. Intestinal permeability is increased in children with nonalcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis. 2014;46:556–560.CrossRefPubMed Giorgio V, Miele L, Principessa L, et al. Intestinal permeability is increased in children with nonalcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis. 2014;46:556–560.CrossRefPubMed
79.
Zurück zum Zitat Luther J, Garber JJ, Khalili H, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol. 2015;1:222–232.CrossRefPubMedPubMedCentral Luther J, Garber JJ, Khalili H, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell Mol Gastroenterol Hepatol. 2015;1:222–232.CrossRefPubMedPubMedCentral
80.
Zurück zum Zitat Teixeira TF, Collado MC, Ferreira CL, Bressan J, Peluzio Mdo C. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr Res. 2012;32:637–647.CrossRefPubMed Teixeira TF, Collado MC, Ferreira CL, Bressan J, Peluzio Mdo C. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr Res. 2012;32:637–647.CrossRefPubMed
81.
Zurück zum Zitat Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–1887.CrossRefPubMed Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–1887.CrossRefPubMed
82.
Zurück zum Zitat Schneider KM, Bieghs V, Heymann F, et al. CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: limiting steatohepatitis by maintaining intestinal homeostasis. Hepatology. 2015;62:1405–1416.CrossRefPubMed Schneider KM, Bieghs V, Heymann F, et al. CX3CR1 is a gatekeeper for intestinal barrier integrity in mice: limiting steatohepatitis by maintaining intestinal homeostasis. Hepatology. 2015;62:1405–1416.CrossRefPubMed
83.
Zurück zum Zitat Vonghia L, Francque S. Cross talk of the immune system in the adipose tissue and the liver in nonalcoholic steatohepatitis: pathology and beyond. World J Hepatol. 2015;7:1905–1912.CrossRefPubMedPubMedCentral Vonghia L, Francque S. Cross talk of the immune system in the adipose tissue and the liver in nonalcoholic steatohepatitis: pathology and beyond. World J Hepatol. 2015;7:1905–1912.CrossRefPubMedPubMedCentral
84.
Zurück zum Zitat Ramadori P, Kroy D, Streetz KL. Immunoregulation by lipids during the development of nonalcoholic steatohepatitis. Hepatobiliary Surg Nutr. 2015;4:11–23.PubMedPubMedCentral Ramadori P, Kroy D, Streetz KL. Immunoregulation by lipids during the development of nonalcoholic steatohepatitis. Hepatobiliary Surg Nutr. 2015;4:11–23.PubMedPubMedCentral
85.
Zurück zum Zitat Moschen AR, Wieser V, Tilg H. Adiponectin: key player in the adipose tissue-liver crosstalk. Curr Med Chem. 2012;19:5467–5473.CrossRefPubMed Moschen AR, Wieser V, Tilg H. Adiponectin: key player in the adipose tissue-liver crosstalk. Curr Med Chem. 2012;19:5467–5473.CrossRefPubMed
86.
Zurück zum Zitat Wan J, Benkdane M, Teixeira-Clerc F, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology. 2014;59:130–142.CrossRefPubMed Wan J, Benkdane M, Teixeira-Clerc F, et al. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology. 2014;59:130–142.CrossRefPubMed
87.
Zurück zum Zitat Arrese M, Cabrera D, Barrera F. Obeticholic acid: expanding the therapeutic landscape of NASH. Ann Hepatol. 2015;14:430–432.PubMed Arrese M, Cabrera D, Barrera F. Obeticholic acid: expanding the therapeutic landscape of NASH. Ann Hepatol. 2015;14:430–432.PubMed
88.
Zurück zum Zitat Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Invest Drugs. 2014;23:1441–1448.CrossRef Cariou B, Staels B. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. Expert Opin Invest Drugs. 2014;23:1441–1448.CrossRef
Metadaten
Titel
Innate Immunity and Inflammation in NAFLD/NASH
verfasst von
Marco Arrese
Daniel Cabrera
Alexis M. Kalergis
Ariel E. Feldstein
Publikationsdatum
03.02.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4049-x

Weitere Artikel der Ausgabe 5/2016

Digestive Diseases and Sciences 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.